Aileron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Aivado Manuel
Aileron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Musso Alan A
Aileron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ambros Reinhard J.
Aileron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Fairey William
Aileron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director VON RICKENBACH JOSEF H
Aileron Therapeutics | 8-K: Current report
Aileron Therapeutics | 8-K: Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Aileron Therapeutics | 10-Q: Q2 2024 Earnings Report
Aileron Therapeutics | 8-K: Current report
Aileron Therapeutics | 424B5: Prospectus
Aileron Therapeutics | 424B5: Prospectus
Aileron Therapeutics | ARS: Annual Report to Security Holders
Aileron Therapeutics | DEFA14A: Others
Aileron Therapeutics | DEF 14A: Definitive information statements
Aileron Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO
Aileron Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO
Aileron Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO
Aileron Therapeutics | 8-K: Current report
Aileron Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Cunningham Timothy M.
Aileron Therapeutics | 8-K: Current report
No Data
No Data